Developer docs
API playgroundTry for free, no card

Search company profiles

Ribo Biotech

Full company profile

uuid00033vx

Namestring
Ribo Biotech
Legal namestring
Suzhou Ribo Life Science Co., Ltd.
Websiteurl
ribolia.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Ribo Biotech (Suzhou Ribo Life Science Co., Ltd.; HKEX: 06938.HK) is a China-headquartered, globally integrated siRNA drug development company founded in 2007 in Kunshan, Jiangsu. The company operates a vertically integrated platform covering the full siRNA drug lifecycle — from sequence design and chemical modification through clinical development and global commercialization — anchored by four proprietary delivery technology platforms: RiboGalSTAR™ (GalNAc-conjugated liver-targeting, with 7 clinical programs), RiboOncoSTAR™ (tumor-targeting), RiboPepSTAR™ (extrahepatic delivery to kidney, CNS, adipose, and muscle), and RSC chemical modification technology. The pipeline includes RBD4059 (FXI siRNA for thrombosis, the world's first FXI-targeting siRNA in clinical development), RBD1016 (HBV/HDV with EMA Orphan Drug Designation), RBD7022 (PCSK9), RBD5044 (ApoC3), RBD7007/RBD2080 (complement C5/C3), and RBD1119 (thrombosis-related), addressing cardiovascular, metabolic, renal, liver, and rare diseases.

The company generates revenue exclusively through licensing and co-development arrangements with global pharmaceutical partners, including a $4.4 billion global MASH license with Madrigal Pharmaceuticals (February 2026), a $2 billion+ NASH/MASH collaboration with Boehringer Ingelheim (January 2024), and a 700M+ RMB Greater China license with Qilu Pharmaceutical for RBD7022 (December 2023). Revenue streams include upfront payments, clinical and regulatory milestone payments, and tiered royalties; for assets with retained global rights (e.g., RBD4059, RBD1119), the company intends to pursue direct commercialization. The company maintains R&D operations in Kunshan, Beijing, and Gothenburg (Sweden), holds EU GMP certification for its Kunshan manufacturing facility, and operates clinical trials across China, EU, Australia, and Hong Kong. It completed an IPO on the Hong Kong Stock Exchange on January 9, 2026.

Ribo employs 101–250 staff across its Kunshan headquarters, Beijing R&D sites, and Ribocure Pharmaceuticals AB subsidiary in Sweden. The leadership team includes co-founders Dr. Zicai Liang (Chairman & CEO) and Dr. Hongyan Zhang (Founding President), both trained at Uppsala University and Yale; Co-CEO Dr. Liming Gan (former AstraZeneca global VP, 20+ years CRM drug development experience); CBO Dr. John Taylor (former AstraZeneca, Pfizer); and CMO Dr. Anders Gabrielsen (Bayer, Novartis, AstraZeneca background). The company partners with academic institutions including Karolinska Institute, Uppsala University, University of Gothenburg, and Mayo Clinic, and has AI collaborations with Insilico Medicine and Pheiron to accelerate drug discovery and optimization.

Short descriptiontext

Ribo Biotech (HKEX: 06938.HK) is a China-based, globally integrated siRNA drug developer that designs and advances clinical-stage RNA interference therapeutics for cardiovascular, metabolic, renal, liver, and rare diseases, generating revenue through licensing and milestone payments from global pharmaceutical partners including Madrigal, Boehringer Ingelheim, and Qilu.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
siRNA therapeutics, RNA interference drugs, oligonucleotide drug development, nucleic acid drug platform, small interfering RNA
Industry4 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oligonucleotide Therapeutics (siRNA Drugs)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Ribo generates revenue through upfront payments, clinical development milestones, regulatory milestones, and sales-based royalties from platform and product licensing deals with global pharmaceutical partners. Notable deals include Madrigal (up to $4.4 billion), Boehringer Ingelheim (over $2 billion), and Qilu Pharmaceutical (over 700 million RMB).

ribolia.com
2Product Development and Commercialization (Retained Rights)
TypeOne Time License
Description

Ribo retains global commercial rights for products not out-licensed, including RBD4059 (FXI targeting, global rights) and RBD1119. Revenue would come from future product sales if approved.

ribolia.com
3Collaborative R&D Funding
TypeProfessional Services
Description

Strategic partnerships provide co-development funding and R&D cost sharing, particularly for co-development arrangements like those with Boehringer Ingelheim and Madrigal.

ribolia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ribo Biotech is a clinical-stage biopharmaceutical company that discovers, develops and licenses small interfering RNA (siRNA) therapeutics built on proprietary liver-targeting (RiboGalSTAR™), extrahepatic (RiboPepSTAR™), tumor-targeting (RiboOncoSTAR™) and chemical modification (RSC) platforms. The company operates a vertically integrated pipeline from early research through global clinical development, advancing seven clinical-stage drug candidates (RBD4059, RBD7022, RBD5044, RBD1016, RBD7007, RBD2080, RBD1119) targeting cardiovascular, metabolic, renal, hepatic and rare diseases, and monetizes these assets through licensing, milestone, and royalty arrangements with global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 7 clinical-stage siRNA programs in Phase I/II
+6 more records
Product overview1 text field

Ribo Biotech is a globally integrated siRNA drug development company with a vertically integrated platform covering the full lifecycle from early research to commercialization. The core offering comprises proprietary delivery technology platforms — RiboGalSTAR™ (liver-targeting), RiboOncoSTARTM (tumor-targeting), RiboPepSTAR™ (extrahepatic organ-targeting), RiboCygnus™, RiboColorSTAR™, and RiboPLEX™ — complemented by the RSC chemical modification platform, Multi-Target Drug Development Platform, siRNA Sequence Design and Screening Platform, and Model-Informed Drug Development (MIDD) Platform. The pipeline includes multiple clinical-stage siRNA drug candidates: RBD4059 (FXI, thrombosis), RBD7022 (PCSK9, hypercholesterolemia), RBD5044 (ApoC3, hypertriglyceridemia), RBD1016 (HBV/HDV, hepatitis), RBD7007 (C5 complement, renal), RBD2080 (C3 complement, renal), RBD1119 (thrombosis-related, coronary artery disease), and additional preclinical candidates across cardiovascular, metabolic, renal, liver, and oncology indications.

Product and service11 records
1RiboGalSTAR™ Liver-Targeting Delivery Platform
CategoryTechnology Platform (Licensed)
Description

Proprietary GalNAc-conjugated siRNA liver-targeting delivery technology enabling precise and effective delivery to hepatic tissues, with seven programs advanced into clinical development and clinically validated safety, efficacy and long-acting profile. Licensed as a standalone platform asset to global pharmaceutical partners.

2RiboPepSTAR™ Extrahepatic Delivery Platform
CategoryTechnology Platform (Licensed)
Description

Molecular conjugation-based delivery platform enabling siRNA targeting to kidneys, CNS, adipose tissue, and muscle, with up to 80% gene knockdown in proximal tubular cells and 96% knockdown in adipose tissue demonstrated in NHP models. Licensed as a standalone platform asset to global pharmaceutical partners.

3RiboOncoSTAR™ Tumor-Targeting Delivery Platform
CategoryTechnology Platform (Licensed)
Description

First extrahepatic delivery technology offering targeted delivery to various tumor tissues including glioma and pancreatic cancer, with superior anti-tumor effects and safety profiles versus standard-of-care demonstrated in preclinical studies. Licensed as a standalone platform asset to oncology partners.

4RSC (Ribo Stabilization Chemistry) Chemical Modification Platform
CategoryTechnology Platform (Licensed)
Description

Iterative siRNA chemical modification technology based on systematic studies of degradation mechanisms, sequence activity, off-target rules and durability, synergizing with delivery technologies to enable lower dosing and prolonged duration. Licensed as a standalone platform asset to global pharmaceutical partners.

5RBD4059 (vortosiran)
CategorysiRNA Drug Candidate (Thrombosis / Cardiovascular)
Description

GalNAc-siRNA drug targeting coagulation factor XI (FXI) for the treatment of thrombotic diseases; the world's first and most advanced siRNA targeting FXI in clinical development (First-In-Modality). Phase I completed in Australia and Phase IIa approved by EMA with all participants enrolled. Ribo retains global commercial rights.

6RBD7022
CategorysiRNA Drug Candidate (Hypercholesterolemia / Cardiovascular)
Description

GalNAc-siRNA drug targeting PCSK9 for treatment of hypercholesterolemia, inhibiting PCSK9 expression to reduce LDL-C levels. Phase I completed in China, Phase II ongoing; licensed exclusively to Qilu Pharmaceutical for development, manufacture and commercialization in Greater China. Phase III being initiated. Ribo retains ex-China global rights.

7RBD5044
CategorysiRNA Drug Candidate (Hypertriglyceridemia / Cardiovascular)
Description

GalNAc-siRNA drug targeting ApoC3 for treatment of hypertriglyceridemia; the second siRNA globally to enter clinical development targeting ApoC3. Phase I completed in Australia with favorable safety and robust long-acting effects supporting quarterly or bi-annual dosing; Phase II clinical trial application approved by EMA.

8RBD1016
CategorysiRNA Drug Candidate (Hepatitis B/D / Liver Disease)
Description

First GalNAc-siRNA based on RiboGalSTAR™ for the treatment of chronic hepatitis B (CHB), covering genotypes A-E and I, also being developed for chronic hepatitis D (CHD). Showed strong and sustained HBsAg reduction up to 6 months in Phase II studies. Phase II MRCT ongoing in Sweden and Hong Kong; received EMA orphan drug designation for HDV in October 2025.

9RBD7007
CategorysiRNA Drug Candidate (Complement-Mediated / Renal Disease)
Description

GalNAc-siRNA targeting complement component C5 for treatment of complement-mediated diseases including renal and autoimmune diseases. Demonstrated robust and long-duration pharmacological effects in cynomolgus monkeys. Phase I clinical trial application approved by EMA.

10RBD2080
CategorysiRNA Drug Candidate (Complement-Mediated / Renal Disease)
Description

GalNAc-siRNA targeting complement component C3 for treatment of complement-mediated diseases including renal and autoimmune diseases. First-in-human Phase I clinical trial application approved in Australia.

11RBD1119
CategorysiRNA Drug Candidate (Coronary Artery Disease / Cardiovascular)
Description

siRNA drug targeting a thrombosis-related factor for treatment of coronary artery disease. Phase II clinical trial application submitted to EMA in May 2026. Ribo retains global rights.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2026-05-12
Description

Strategic AI+siRNA collaboration leveraging Insilico's Pharma.AI platform and automated biology labs alongside Ribo's siRNA technology and development capabilities. Covers target discovery, drug design and optimization, AI-assisted drug R&D and clinical translation. Insilico became Ribo's first high-throughput experimental service partner for LifeStar 2 automated lab platform in 2025. This strategic upgrade builds on prior collaboration integrating AI algorithms with siRNA development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Global exclusive license agreement for six pre-clinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). Ribo granted Madrigal exclusive worldwide rights for R&D, manufacturing and commercialization of the programs. Ribo receives $60 million upfront payment with potential milestones and royalties totaling up to $4.4 billion, plus tiered royalties on net sales. Madrigal, the company behind the first FDA-approved MASH drug (Rezdiffra/resmetirom), gains access to Ribo's liver-targeting siRNA platform for multi-mechanism MASH treatment.

Strategic tierImportantTypeTechnology or IntegrationAnnounced on2024-09-24
Description

AI-assisted RNA drug development collaboration using Pheiron's advanced AI platform (PheironGPS) to accelerate Ribo's RNA therapeutics pipeline. First two milestones achieved in March 2025, demonstrating early success in applying AI to siRNA target identification and sequence optimization.

4Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-03
Description

Multi-target collaboration for developing siRNA therapeutics for NASH/MASH and broader liver diseases. Ribo contributes its RIBO-GalSTAR™ liver-targeting platform and early-stage research capabilities. Boehringer Ingelheim contributes its cardiovascular, renal, and metabolic disease (CRM) expertise and global clinical development and commercialization capabilities. Deal includes upfront payment, clinical and regulatory milestones, and tiered sales royalties totaling over $2 billion. Multiple milestones achieved including third milestone in May 2026.

ribolia.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-25
Description

Exclusive license agreement for RBD7022 (PCSK9-targeting siRNA) in Greater China (mainland China, Hong Kong, Macau). Qilu obtained rights for clinical development, manufacturing, and commercialization in the Greater China region. Ribo retained ex-China global rights. Deal valued at over 700 million RMB including upfront and milestones plus tiered royalties. Phase II completed with 204 patients; Phase III planned to start in China.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2017-04-01
Description

Strategic collaboration with global oligonucleotide pharmaceutical leader Ionis, USA (announced April 2017). This collaboration established Ribo as a recognized partner in the global oligonucleotide field and contributed to technology platform development. Product ISIS560131 (antisense oligonucleotide for prostate cancer) was developed under this partnership with exclusive rights for China development and commercialization.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2012-09-01
Description

Strategic collaboration established in 2012 to form a joint venture company (Suzhou Ribo Quark) for siRNA drug development. Under this partnership, QPI-1007 became China's first approved siRNA drug for clinical trials (IND approved December 2015). Joint venture company Ribo Quark received $7 million first-round financing in November 2013.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

London-listed siRNA developer with the mRNAi GOLD platform, focused on cardiometabolic and rare diseases with partnered programs (e.g., with AstraZeneca, Hansoh). Directly comparable to Ribo in modality, target organs (liver via GalNAc), and business model (platform licensing and product development).

TypeEmerging player
Description

Clinical-stage immunology company developing siRNA and other modalities for chronic hepatitis B and hepatitis D. Directly comparable to Ribo's RBD1016 program in HBV/HDV and represents a focused competitor in the same infectious disease liver space.

TypeDirect peer
Description

The leading antisense oligonucleotide (ASO) platform company and a foundational Ribo partner since 2017. Ionis overlaps with Ribo in oligonucleotide-based drug development for cardiometabolic, hepatic, and rare diseases, and serves as a comparable platform licensor with multiple approved products.

TypeDirect peer
Description

US-based siRNA developer with the TRiM (Targeted RNAi Molecule) platform for extrahepatic and liver delivery. Comparable to Ribo in pursuing cardiometabolic and liver indications, with overlapping targets (e.g., HBV, cardiovascular targets) and a similar platform-plus-product licensing business model.

TypeDirect peer
Description

The global leader in siRNA therapeutics and the pioneer of GalNAc liver-targeted delivery, with multiple approved products (Onpattro, Givlaari, Oxlumo, Leqvio, Amvuttra). Alnylam is the most directly comparable competitor to Ribo's RiboGalSTAR platform and overlaps in cardiometabolic, liver, and rare disease indications.

TypeBroad incumbent
Description

Dicerna's GalXC siRNA platform was acquired by Novo Nordisk in 2021, creating an integrated large-pharma siRNA capability. Relevant as a broad incumbent that has absorbed a direct siRNA peer, illustrating both the strategic value of siRNA platforms and the competitive threat from large-pharma integration.

TypeDirect peer
Description

Clinical-stage oligonucleotide therapeutics company with a stereopure PRISM platform. Wave is comparable to Ribo as a platform-driven oligonucleotide developer pursuing hepatic, neurological, and rare disease targets, though Wave focuses on ASO and RNAi silencing modalities.

TypeDirect peer
Description

China-based siRNA drug developer with a GalNAc platform and pipeline in rare diseases and oncology. Closest Chinese direct competitor to Ribo in modality, platform approach, and disease focus, and an alternative origination source for MNCs seeking China siRNA assets.

TypeEmerging player
Description

China-based siRNA developer with a delivery platform and pipeline spanning cardiovascular, metabolic, and rare diseases. Comparable to Ribo as another Chinese siRNA originator competing for BD deals and clinical development resources within China.

TypeDirect peer
Description

China-based siRNA biotech with a GalNAc delivery platform and pipeline targeting cardiometabolic and renal diseases. Directly comparable to Ribo as a domestic Chinese siRNA developer pursuing similar indications with similar chemistry and delivery approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ribo Biotech

Oligonucleotide Therapeutics (siRNA Drugs)ribolia.com

Ribo Biotech (HKEX: 06938.HK) is a China-based, globally integrated siRNA drug developer that designs and advances clinical-stage RNA interference therapeutics for cardiovascular, metabolic, renal, liver, and rare diseases, generating revenue through licensing and milestone payments from global pharmaceutical partners including Madrigal, Boehringer Ingelheim, and Qilu.

What Ribo Biotech does

Ribo Biotech (Suzhou Ribo Life Science Co., Ltd.; HKEX: 06938.HK) is a China-headquartered, globally integrated siRNA drug development company founded in 2007 in Kunshan, Jiangsu. The company operates a vertically integrated platform covering the full siRNA drug lifecycle — from sequence design and chemical modification through clinical development and global commercialization — anchored by four proprietary delivery technology platforms: RiboGalSTAR™ (GalNAc-conjugated liver-targeting, with 7 clinical programs), RiboOncoSTAR™ (tumor-targeting), RiboPepSTAR™ (extrahepatic delivery to kidney, CNS, adipose, and muscle), and RSC chemical modification technology. The pipeline includes RBD4059 (FXI siRNA for thrombosis, the world's first FXI-targeting siRNA in clinical development), RBD1016 (HBV/HDV with EMA Orphan Drug Designation), RBD7022 (PCSK9), RBD5044 (ApoC3), RBD7007/RBD2080 (complement C5/C3), and RBD1119 (thrombosis-related), addressing cardiovascular, metabolic, renal, liver, and rare diseases.

The company generates revenue exclusively through licensing and co-development arrangements with global pharmaceutical partners, including a $4.4 billion global MASH license with Madrigal Pharmaceuticals (February 2026), a $2 billion+ NASH/MASH collaboration with Boehringer Ingelheim (January 2024), and a 700M+ RMB Greater China license with Qilu Pharmaceutical for RBD7022 (December 2023). Revenue streams include upfront payments, clinical and regulatory milestone payments, and tiered royalties; for assets with retained global rights (e.g., RBD4059, RBD1119), the company intends to pursue direct commercialization. The company maintains R&D operations in Kunshan, Beijing, and Gothenburg (Sweden), holds EU GMP certification for its Kunshan manufacturing facility, and operates clinical trials across China, EU, Australia, and Hong Kong. It completed an IPO on the Hong Kong Stock Exchange on January 9, 2026.

Ribo employs 101–250 staff across its Kunshan headquarters, Beijing R&D sites, and Ribocure Pharmaceuticals AB subsidiary in Sweden. The leadership team includes co-founders Dr. Zicai Liang (Chairman & CEO) and Dr. Hongyan Zhang (Founding President), both trained at Uppsala University and Yale; Co-CEO Dr. Liming Gan (former AstraZeneca global VP, 20+ years CRM drug development experience); CBO Dr. John Taylor (former AstraZeneca, Pfizer); and CMO Dr. Anders Gabrielsen (Bayer, Novartis, AstraZeneca background). The company partners with academic institutions including Karolinska Institute, Uppsala University, University of Gothenburg, and Mayo Clinic, and has AI collaborations with Insilico Medicine and Pheiron to accelerate drug discovery and optimization.

Ribo Biotech firmographics

Firmographics
Name
Ribo Biotech
Legal name
Suzhou Ribo Life Science Co., Ltd.
Website
https://ribolia.com
Company type
Public
Founded year
2007
Operating status
Ipo
Headcount range
11–50 employees
Short description
Ribo Biotech (HKEX: 06938.HK) is a China-based, globally integrated siRNA drug developer that designs and advances clinical-stage RNA interference therapeutics for cardiovascular, metabolic, renal, liver, and rare diseases, generating revenue through licensing and milestone payments from global pharmaceutical partners including Madrigal, Boehringer Ingelheim, and Qilu.
Ownership category
akta.pro rank

Ribo Biotech industry classification

Industry
Product category
Oligonucleotide Therapeutics (siRNA Drugs)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • SiRNA therapeutics
  • RNA interference drugs
  • Oligonucleotide drug development
  • Nucleic acid drug platform
  • Small interfering RNA

Where Ribo Biotech is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Ribo Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Milestone Payments: Ribo generates revenue through upfront payments, clinical development milestones, regulatory milestones, and sales-based royalties from platform and product licensing deals with global pharmaceutical partners. Notable deals include Madrigal (up to $4.4 billion), Boehringer Ingelheim (over $2 billion), and Qilu Pharmaceutical (over 700 million RMB).
  2. Product Development and Commercialization (Retained Rights): Ribo retains global commercial rights for products not out-licensed, including RBD4059 (FXI targeting, global rights) and RBD1119. Revenue would come from future product sales if approved.
  3. Collaborative R&D Funding: Strategic partnerships provide co-development funding and R&D cost sharing, particularly for co-development arrangements like those with Boehringer Ingelheim and Madrigal.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Ribo Biotech product offering

Product offering

Core offering

Ribo Biotech is a clinical-stage biopharmaceutical company that discovers, develops and licenses small interfering RNA (siRNA) therapeutics built on proprietary liver-targeting (RiboGalSTAR™), extrahepatic (RiboPepSTAR™), tumor-targeting (RiboOncoSTAR™) and chemical modification (RSC) platforms. The company operates a vertically integrated pipeline from early research through global clinical development, advancing seven clinical-stage drug candidates (RBD4059, RBD7022, RBD5044, RBD1016, RBD7007, RBD2080, RBD1119) targeting cardiovascular, metabolic, renal, hepatic and rare diseases, and monetizes these assets through licensing, milestone, and royalty arrangements with global pharmaceutical partners.

Product overview

Ribo Biotech is a globally integrated siRNA drug development company with a vertically integrated platform covering the full lifecycle from early research to commercialization. The core offering comprises proprietary delivery technology platforms — RiboGalSTAR™ (liver-targeting), RiboOncoSTARTM (tumor-targeting), RiboPepSTAR™ (extrahepatic organ-targeting), RiboCygnus™, RiboColorSTAR™, and RiboPLEX™ — complemented by the RSC chemical modification platform, Multi-Target Drug Development Platform, siRNA Sequence Design and Screening Platform, and Model-Informed Drug Development (MIDD) Platform. The pipeline includes multiple clinical-stage siRNA drug candidates: RBD4059 (FXI, thrombosis), RBD7022 (PCSK9, hypercholesterolemia), RBD5044 (ApoC3, hypertriglyceridemia), RBD1016 (HBV/HDV, hepatitis), RBD7007 (C5 complement, renal), RBD2080 (C3 complement, renal), RBD1119 (thrombosis-related, coronary artery disease), and additional preclinical candidates across cardiovascular, metabolic, renal, liver, and oncology indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • RiboGalSTAR™ Liver-Targeting Delivery Platform Proprietary GalNAc-conjugated siRNA liver-targeting delivery technology enabling precise and effective delivery to hepatic tissues, with seven programs advanced into clinical development and clinically validated safety, efficacy and long-acting profile. Licensed as a standalone platform asset to global pharmaceutical partners.
  • RiboPepSTAR™ Extrahepatic Delivery Platform Molecular conjugation-based delivery platform enabling siRNA targeting to kidneys, CNS, adipose tissue, and muscle, with up to 80% gene knockdown in proximal tubular cells and 96% knockdown in adipose tissue demonstrated in NHP models. Licensed as a standalone platform asset to global pharmaceutical partners.
  • RiboOncoSTAR™ Tumor-Targeting Delivery Platform First extrahepatic delivery technology offering targeted delivery to various tumor tissues including glioma and pancreatic cancer, with superior anti-tumor effects and safety profiles versus standard-of-care demonstrated in preclinical studies. Licensed as a standalone platform asset to oncology partners.
  • RSC (Ribo Stabilization Chemistry) Chemical Modification Platform Iterative siRNA chemical modification technology based on systematic studies of degradation mechanisms, sequence activity, off-target rules and durability, synergizing with delivery technologies to enable lower dosing and prolonged duration. Licensed as a standalone platform asset to global pharmaceutical partners.
  • RBD4059 (vortosiran) GalNAc-siRNA drug targeting coagulation factor XI (FXI) for the treatment of thrombotic diseases; the world's first and most advanced siRNA targeting FXI in clinical development (First-In-Modality). Phase I completed in Australia and Phase IIa approved by EMA with all participants enrolled. Ribo retains global commercial rights.
  • RBD7022 GalNAc-siRNA drug targeting PCSK9 for treatment of hypercholesterolemia, inhibiting PCSK9 expression to reduce LDL-C levels. Phase I completed in China, Phase II ongoing; licensed exclusively to Qilu Pharmaceutical for development, manufacture and commercialization in Greater China. Phase III being initiated. Ribo retains ex-China global rights.
  • RBD5044 GalNAc-siRNA drug targeting ApoC3 for treatment of hypertriglyceridemia; the second siRNA globally to enter clinical development targeting ApoC3. Phase I completed in Australia with favorable safety and robust long-acting effects supporting quarterly or bi-annual dosing; Phase II clinical trial application approved by EMA.
  • RBD1016 First GalNAc-siRNA based on RiboGalSTAR™ for the treatment of chronic hepatitis B (CHB), covering genotypes A-E and I, also being developed for chronic hepatitis D (CHD). Showed strong and sustained HBsAg reduction up to 6 months in Phase II studies. Phase II MRCT ongoing in Sweden and Hong Kong; received EMA orphan drug designation for HDV in October 2025.
  • RBD7007 GalNAc-siRNA targeting complement component C5 for treatment of complement-mediated diseases including renal and autoimmune diseases. Demonstrated robust and long-duration pharmacological effects in cynomolgus monkeys. Phase I clinical trial application approved by EMA.
  • RBD2080 GalNAc-siRNA targeting complement component C3 for treatment of complement-mediated diseases including renal and autoimmune diseases. First-in-human Phase I clinical trial application approved in Australia.
  • RBD1119 siRNA drug targeting a thrombosis-related factor for treatment of coronary artery disease. Phase II clinical trial application submitted to EMA in May 2026. Ribo retains global rights.

Quantifiable outcome

  • 7 clinical-stage siRNA programs in Phase I/II
  • +6 more outcomes

Companies that use Ribo Biotech

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Ribo Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Ribo Biotech partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered important, core and foundational.

  • Insilico Medicine (英矽智能)importantTechnology or Integration · 12 May 2026Strategic AI+siRNA collaboration leveraging Insilico's Pharma.AI platform and automated biology labs alongside Ribo's siRNA technology and development capabilities. Covers target discovery, drug design and optimization, AI-assisted drug R&D and clinical translation. Insilico became Ribo's first high-throughput experimental service partner for LifeStar 2 automated lab platform in 2025. This strategic upgrade builds on prior collaboration integrating AI algorithms with siRNA development.
  • Madrigal Pharmaceuticals, Inc.coreStrategic or Co-development Partner · 11 February 2026Global exclusive license agreement for six pre-clinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). Ribo granted Madrigal exclusive worldwide rights for R&D, manufacturing and commercialization of the programs. Ribo receives $60 million upfront payment with potential milestones and royalties totaling up to $4.4 billion, plus tiered royalties on net sales. Madrigal, the company behind the first FDA-approved MASH drug (Rezdiffra/resmetirom), gains access to Ribo's liver-targeting siRNA platform for multi-mechanism MASH treatment.
  • PheironimportantTechnology or Integration · 24 September 2024AI-assisted RNA drug development collaboration using Pheiron's advanced AI platform (PheironGPS) to accelerate Ribo's RNA therapeutics pipeline. First two milestones achieved in March 2025, demonstrating early success in applying AI to siRNA target identification and sequence optimization.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 3 January 2024Multi-target collaboration for developing siRNA therapeutics for NASH/MASH and broader liver diseases. Ribo contributes its RIBO-GalSTAR™ liver-targeting platform and early-stage research capabilities. Boehringer Ingelheim contributes its cardiovascular, renal, and metabolic disease (CRM) expertise and global clinical development and commercialization capabilities. Deal includes upfront payment, clinical and regulatory milestones, and tiered sales royalties totaling over $2 billion. Multiple milestones achieved including third milestone in May 2026.
  • Qilu Pharmaceutical Co., Ltd. (齐鲁制药)coreChannel Partner/ Reseller/ Distributor · 25 December 2023Exclusive license agreement for RBD7022 (PCSK9-targeting siRNA) in Greater China (mainland China, Hong Kong, Macau). Qilu obtained rights for clinical development, manufacturing, and commercialization in the Greater China region. Ribo retained ex-China global rights. Deal valued at over 700 million RMB including upfront and milestones plus tiered royalties. Phase II completed with 204 patients; Phase III planned to start in China.
  • Ionis PharmaceuticalsfoundationalStrategic or Co-development Partner · 1 April 2017Strategic collaboration with global oligonucleotide pharmaceutical leader Ionis, USA (announced April 2017). This collaboration established Ribo as a recognized partner in the global oligonucleotide field and contributed to technology platform development. Product ISIS560131 (antisense oligonucleotide for prostate cancer) was developed under this partnership with exclusive rights for China development and commercialization.
  • Quark Pharmaceuticals, Inc. (美国夸克制药)foundationalStrategic or Co-development Partner · 1 September 2012Strategic collaboration established in 2012 to form a joint venture company (Suzhou Ribo Quark) for siRNA drug development. Under this partnership, QPI-1007 became China's first approved siRNA drug for clinical trials (IND approved December 2015). Joint venture company Ribo Quark received $7 million first-round financing in November 2013.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Ribo Biotech competitors and assessment

Company assessment

Direct peers

  • Silence Therapeutics: London-listed siRNA developer with the mRNAi GOLD platform, focused on cardiometabolic and rare diseases with partnered programs (e.g., with AstraZeneca, Hansoh). Directly comparable to Ribo in modality, target organs (liver via GalNAc), and business model (platform licensing and product development).
  • Ionis Pharmaceuticals: The leading antisense oligonucleotide (ASO) platform company and a foundational Ribo partner since 2017. Ionis overlaps with Ribo in oligonucleotide-based drug development for cardiometabolic, hepatic, and rare diseases, and serves as a comparable platform licensor with multiple approved products.
  • Arrowhead Pharmaceuticals: US-based siRNA developer with the TRiM (Targeted RNAi Molecule) platform for extrahepatic and liver delivery. Comparable to Ribo in pursuing cardiometabolic and liver indications, with overlapping targets (e.g., HBV, cardiovascular targets) and a similar platform-plus-product licensing business model.
  • Alnylam Pharmaceuticals: The global leader in siRNA therapeutics and the pioneer of GalNAc liver-targeted delivery, with multiple approved products (Onpattro, Givlaari, Oxlumo, Leqvio, Amvuttra). Alnylam is the most directly comparable competitor to Ribo's RiboGalSTAR platform and overlaps in cardiometabolic, liver, and rare disease indications.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with a stereopure PRISM platform. Wave is comparable to Ribo as a platform-driven oligonucleotide developer pursuing hepatic, neurological, and rare disease targets, though Wave focuses on ASO and RNAi silencing modalities.
  • Ractigen Therapeutics: China-based siRNA drug developer with a GalNAc platform and pipeline in rare diseases and oncology. Closest Chinese direct competitor to Ribo in modality, platform approach, and disease focus, and an alternative origination source for MNCs seeking China siRNA assets.
  • Sanegene Bio: China-based siRNA biotech with a GalNAc delivery platform and pipeline targeting cardiometabolic and renal diseases. Directly comparable to Ribo as a domestic Chinese siRNA developer pursuing similar indications with similar chemistry and delivery approaches.

Emerging players

  • Vir Biotechnology: Clinical-stage immunology company developing siRNA and other modalities for chronic hepatitis B and hepatitis D. Directly comparable to Ribo's RBD1016 program in HBV/HDV and represents a focused competitor in the same infectious disease liver space.
  • Argo Biopharmaceutical: China-based siRNA developer with a delivery platform and pipeline spanning cardiovascular, metabolic, and rare diseases. Comparable to Ribo as another Chinese siRNA originator competing for BD deals and clinical development resources within China.

Broad incumbents

  • Dicerna Pharmaceuticals (Novo Nordisk): Dicerna's GalXC siRNA platform was acquired by Novo Nordisk in 2021, creating an integrated large-pharma siRNA capability. Relevant as a broad incumbent that has absorbed a direct siRNA peer, illustrating both the strategic value of siRNA platforms and the competitive threat from large-pharma integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ribo Biotech social profiles

Digital presence

Ribo Biotech compliance and trust

Trust signal

Compliance2 records

Ribo Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ribo Biotech leadership team

Management profile

Number of profiles

Profiles8 records

Ribo Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ribo Biotech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ribo Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ribo Biotech

What does Ribo Biotech do?

Ribo Biotech is a clinical-stage biopharmaceutical company that discovers, develops and licenses small interfering RNA (siRNA) therapeutics built on proprietary liver-targeting (RiboGalSTAR™), extrahepatic (RiboPepSTAR™), tumor-targeting (RiboOncoSTAR™) and chemical modification (RSC) platforms. The company operates a vertically integrated pipeline from early research through global clinical development, advancing seven clinical-stage drug candidates (RBD4059, RBD7022, RBD5044, RBD1016, RBD7007, RBD2080, RBD1119) targeting cardiovascular, metabolic, renal, hepatic and rare diseases, and monetizes these assets through licensing, milestone, and royalty arrangements with global pharmaceutical partners.

Is Ribo Biotech a public or private company?

Ribo Biotech is a public company. It is classified as public and is currently ipo.

When was Ribo Biotech founded?

Ribo Biotech was founded in 2007. It employs 11 to 50 people.

Where is Ribo Biotech based?

Ribo Biotech is headquartered in Suzhou, China, in the Asia region.

How does Ribo Biotech make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are product Development and Commercialization (Retained Rights) and collaborative R&D Funding.

Who are Ribo Biotech's main competitors?

Direct peers on record are Silence Therapeutics, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Wave Life Sciences, Ractigen Therapeutics and Sanegene Bio. Emerging players are Vir Biotechnology and Argo Biopharmaceutical. Dicerna Pharmaceuticals (Novo Nordisk) is listed as a broad incumbent.

Does Ribo Biotech have an API?

No public API is recorded for Ribo Biotech.

What industry is Ribo Biotech in?

Ribo Biotech's product category is Oligonucleotide Therapeutics (siRNA Drugs). Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals